Last reviewed · How we verify
Intralipid
At a glance
| Generic name | Intralipid |
|---|---|
| Also known as | Lipid, intralipid 20%, Free Fatty Acid, intravenous lipids, Liposyn |
| Sponsor | University of Kansas Medical Center |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNINGS Deaths in preterm infants after infusion of intravenous fat emulsion have been reported in the medical literature 2 . Autopsy findings included intravascular fat accumulation in the lungs. Treatment of premature and low birth weight infants with intravenous fat emulsion must be based upon careful benefit-risk assessment. Strict adherence to the recommended total daily dose is mandatory; hourly infusion rate should be as slow as possible in each case and should not in any case exceed 1 g
Common side effects
- Anemia
- Nausea
- Vomiting
- Gamma-glutamyltransferase increased
- Cholestasis
- Pyrexia
- C-reactive protein increased
- Hyperbilirubinemia
- Bilirubin conjugated increased
- Nosocomial infection
- Blood alkaline phosphatase increased
- Hypertension
Serious adverse events
- Sepsis
- Pneumonia
- Parenteral nutrition-associated liver disease
- Thrombophlebitis
- Cholestasis
- Dyspnea
- Infection
- Urinary tract infection
- Liver function test abnormalities
- Fluid overload
Key clinical trials
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Effects of Lipid Emulsions on Coagulation
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users (PHASE1)
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Food Intake-Related Brain and Metabolic Responses in Obesity (NA)
- Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |